May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Triamcinolone Acetonide Reduces Intravitreous Neovascularization and Central Capillary Density in a Rat Model of Oxygen Induced Retinopathy
Author Affiliations & Notes
  • D.J. Martiniuk
    Ophthalmology, UNC, Chapel Hill, NC
  • J.R. McColm
    Ophthalmology, UNC, Chapel Hill, NC
  • P. Geisen
    Ophthalmology, UNC, Chapel Hill, NC
  • L.J. Peterson
    Ophthalmology, UNC, Chapel Hill, NC
  • Y. Saito
    Ophthalmology, UNC, Chapel Hill, NC
  • W. Smith
    Ophthalmology, UNC, Chapel Hill, NC
  • M.E. Hartnett
    Ophthalmology, UNC, Chapel Hill, NC
  • Footnotes
    Commercial Relationships  D.J. Martiniuk, None; J.R. McColm, None; P. Geisen, None; L.J. Peterson, None; Y. Saito, None; W. Smith, None; M.E. Hartnett, None.
  • Footnotes
    Support  Retina Research Foundation Mills and Margaret Cox Endowment Research to Prevent Blindness; NIH R01 EY015130 HIGHWIRE EXLINK_ID="47:5:4284:1" VALUE="EY015130" TYPEGUESS="GEN" /HIGHWIRE –01A1; ADA 1–05–RA–51
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4284. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.J. Martiniuk, J.R. McColm, P. Geisen, L.J. Peterson, Y. Saito, W. Smith, M.E. Hartnett; Triamcinolone Acetonide Reduces Intravitreous Neovascularization and Central Capillary Density in a Rat Model of Oxygen Induced Retinopathy . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4284.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the effect of intravitreous injections of triamcinolone (TA) on intravitreous neovascularization (IVNV) and existing intraretinal vascularization using a rat model of oxygen induced retinopathy (OIR).

Methods: : Newborn Sprague–Dawley rats and their mothers were placed in an Oxycycler (Biospherix, NY). Oxygen was cycled between 10 and 50% every 24 hours. At p14, rats were removed from the cycler and given a 1µL intravitreous (IV) injection of TA (15, 30 or 60µg/µL) or sterile PBS. TA was washed before injection by replacing supernatant with PBS after centrifugation. After 4 days in room air, rats were euthanized and perfused with 4% paraformaldehyde before the eyes were removed. Following dissection, retinas were flat–mounted and stained with TRITC conjugated Griffonia lectin and caspase–3. IVNV was quantified by counting clock hours (CH), and percent peripheral avascular area of each retina was determined. Central capillary density was quantified by counting vessel junctions within a fixed retinal area. Vessel tortuosities of major posterior pole arteries and veins were measured using vessel extraction software developed at UNC’s Computer Aided Diagnosis and Display Lab.

Results: : Clock hours of IVNV were significantly reduced for each dose of TA vs. non–injected eyes (6.6 ± 2.7, 5.5 ± 3.3, 5.2 ± 3.5 vs. 8.8 ± 2.1, p<0.020, p<0.001, p<0.001, students T–Test, 15, 30, 60µg/µL vs. non–injected respectively). Central capillary density was significantly reduced in 30µg/µL injected eyes vs. non–injected eyes (157 ± 50 vs. 286 ± 77 junctions per 0.64mm^2, p<0.016, students T–Test) and in 60µg/µL injected eyes vs. non–injected eyes (137 ± 29 vs. 286 ± 77 junctions per 0.64mm^2, p<0.009, students T–Test), but not in the 15µg/µL injected eyes. Qualitative analysis of caspase–3 images indicated no increase in apoptosis in each TA treatment group vs. untreated eyes. There were no significant differences in total retinal area, percent peripheral avascular areas, or vessel tortuosities across treatment groups.

Conclusions: : High doses of TA reduce IVNV in an OIR rat model but also reduce central capillary density, which requires further study to understand the mechanism and determine possible concerns with safety.

Keywords: proliferative vitreoretinopathy • retinal neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×